We are live on ! Find out more
HALO icon

Halozyme

410 hedge funds and large institutions have $4.62B invested in Halozyme in 2023 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 147 increasing their positions, 145 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

291% more call options, than puts

Call options by funds: $18.9M | Put options by funds: $4.84M

75% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 36

5% more funds holding

Funds holding: 389410 (+21)

1.14% more ownership

Funds ownership: 93.38%94.53% (+1.1%)

1% more repeat investments, than reductions

Existing positions increased: 147 | Existing positions reduced: 145

2% less capital invested

Capital invested by funds: $4.71B → $4.62B (-$86.5M)

60% less funds holding in top 10

Funds holding in top 10: 52 (-3)

Holders
410
Holders Change
+21
Holders Change %
+5.4%
% of All Funds
5.97%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.03%
New
63
Increased
147
Reduced
145
Closed
36
Calls
$18.9M
Puts
$4.84M
Net Calls
+$14.1M
Net Calls Change
-$740K

HALO Hedge Fund Activity: Q4 2023 in Review

410 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q4 2023, worth a combined $4.62B — down 1.8% from $4.71B a quarter earlier.

Buyers outnumbered sellers: 63 funds opened new HALO positions and 36 closed out — a net gain of 27 holders — while 147 added to existing stakes and 145 trimmed.

The largest buyer was TD Asset Management, adding an estimated $62.6M. The largest seller was Marshall Wace, cutting an estimated $78.3M.

  • 410 institutional investors held Halozyme (HALO) as of Q4 2023, up from 389 in Q3 2023.
  • Funds reported $4.62B of Halozyme stock for Q4 2023, down 1.8% quarter-over-quarter.
  • 63 funds opened new Halozyme positions in Q4 2023 and 36 closed out, a net change of +27 holders.
  • The largest Halozyme buyer in Q4 2023 was TD Asset Management, an estimated $62.6M added.
  • The largest Halozyme seller in Q4 2023 was Marshall Wace, an estimated $78.3M sold.

Based on aggregated 13F filings for Q4 2023.